OSI PHARMA'S TARCEVA APPROVED IN CANADA

OSI Pharmaceuticals has received Canadian approval Tarceva as a treatment for advanced or spreading lung cancer in patients who have not responded to chemotherapy.

The oral drug, which OSI developed with Genentech and Roche, is already approved for this indication in the U.S. and Switzerland. A European regulatory committee also has recommended approval of the drug. The approval applies to patients with non-small cell lung cancer, the most common form of the disease.